120 results on '"van der Schaaf RJ"'
Search Results
2. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial
- Author
-
Tijssen, R.Y.G., Kerkmeijer, L.S.M., Katagiri, Y., Kraak, R. P., Takahashi, K, Kogame, N., Chichareon, P., Modolo, R. (Rodrigo), Asano, T. (Taku), Nassif, M., Kalkman, D.N., Sotomi, Y, Collet, C. (Carlos), Hofma, SH, van der Schaaf, RJ, Arkenbout, E.K. (Elisabeth Karin), Weevers, A., Beijk, M.A.M., Piek, J.J. (Jan), Tijssen, J.G.P. (Jan), Henriques, J.P., Winter, R.J. de, Onuma, Y. (Yoshinobu), Serruys, P.W.J.C. (Patrick), Wykrzykowska, JJ, Tijssen, R.Y.G., Kerkmeijer, L.S.M., Katagiri, Y., Kraak, R. P., Takahashi, K, Kogame, N., Chichareon, P., Modolo, R. (Rodrigo), Asano, T. (Taku), Nassif, M., Kalkman, D.N., Sotomi, Y, Collet, C. (Carlos), Hofma, SH, van der Schaaf, RJ, Arkenbout, E.K. (Elisabeth Karin), Weevers, A., Beijk, M.A.M., Piek, J.J. (Jan), Tijssen, J.G.P. (Jan), Henriques, J.P., Winter, R.J. de, Onuma, Y. (Yoshinobu), Serruys, P.W.J.C. (Patrick), and Wykrzykowska, JJ
- Published
- 2019
- Full Text
- View/download PDF
3. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial
- Author
-
Tijssen, RYG, Kerkmeijer, LSM, Katagiri, Y, Kraak, R P, Takahashi, K, Kogame, N, Chichareon, P, Modolo, R, Asano, T, Nassif, M, Kalkman, DN, Sotomi, Y, Collet, C, Hofma, SH, van der Schaaf, RJ, Arkenbout, EK, Weevers, A, Beijk, MAM, Piek, JJ, Tijssen, JGP, Henriques, JP, de Winter, RJ, Onuma, Yoshinobu, Serruys, PWJC, Wykrzykowska, JJ, Tijssen, RYG, Kerkmeijer, LSM, Katagiri, Y, Kraak, R P, Takahashi, K, Kogame, N, Chichareon, P, Modolo, R, Asano, T, Nassif, M, Kalkman, DN, Sotomi, Y, Collet, C, Hofma, SH, van der Schaaf, RJ, Arkenbout, EK, Weevers, A, Beijk, MAM, Piek, JJ, Tijssen, JGP, Henriques, JP, de Winter, RJ, Onuma, Yoshinobu, Serruys, PWJC, and Wykrzykowska, JJ
- Published
- 2019
4. Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands
- Author
-
ten Haaf, ME, Bax, M, Berg, JM, Brouwer, J, van't Hof, AW, van der Schaaf, RJ, Stella, PR, Gin, R, Tonino, PA, Vries, AG, Zijlstra, Felix, Boersma, Eric, Appelman, Y, ten Haaf, ME, Bax, M, Berg, JM, Brouwer, J, van't Hof, AW, van der Schaaf, RJ, Stella, PR, Gin, R, Tonino, PA, Vries, AG, Zijlstra, Felix, Boersma, Eric, and Appelman, Y
- Published
- 2019
5. Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial
- Author
-
Elias, J, van Dongen, IM, Hoebers, LP, Ouweneel, DM, Claessen, B, Ramunddal, T, Laanmets, P, Eriksen, E, van der Schaaf, RJ, Ioanes, D, Nijveldt, R, Tijssen, JG, Hirsch, Alexander, Henriques, JPS, Elias, J, van Dongen, IM, Hoebers, LP, Ouweneel, DM, Claessen, B, Ramunddal, T, Laanmets, P, Eriksen, E, van der Schaaf, RJ, Ioanes, D, Nijveldt, R, Tijssen, JG, Hirsch, Alexander, and Henriques, JPS
- Published
- 2017
6. Persistent precordial 'hyperacute' T-waves signify proximal left anterior descending artery occlusion.
- Author
-
Verouden NJ, Koch KT, Peters RJ, Henriques JP, Baan J, van der Schaaf RJ, Vis MM, Tijssen JG, Piek JJ, Wellens HJ, Wilde AA, and de Winter RJ
- Abstract
OBJECTIVE: To describe patients with a distinct electrocardiogram (ECG) pattern without ST-segment elevation in the presence of an acute occlusion of the proximal left anterior descending (LAD) artery. DESIGN: Single-centre observational study. PATIENTS: Patients with acute anterior wall myocardial infarction who were referred for primary percutaneous coronary intervention (PCI) between 1998 and 2008. RESULTS: We identified patients with a static, distinct ECG pattern without ST-segment elevation and an occlusion of the proximal LAD artery during urgent coronary angiography before PCI. Of 1890 patients who underwent primary PCI of the LAD artery, we could identify 35 patients (2%) with this distinct ECG pattern. The ECG showed ST-segment depression at the J-point of at least 1 mm in precordial leads with upsloping ST-segments continuing into tall, symmetrical T-waves. Patients with this distinct ECG pattern were younger, more often male and more often had hypercholesterolaemia compared to patients with anterior myocardial infarction and ST-segment elevation. CONCLUSIONS: In patients presenting with chest pain, ST-segment depression at the J-point with upsloping ST-segments and tall, symmetrical T-waves in the precordial leads of the 12-lead ECG signifies proximal LAD artery occlusion. It is important for cardiologists and emergency care physicians to recognise this distinct ECG pattern, so they can triage such patients for immediate reperfusion therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
7. Presence of older thrombus is an independent predictor of long-term mortality in patients with ST-elevation myocardial infarction treated with thrombus aspiration during primary percutaneous coronary intervention.
- Author
-
Kramer MCA, van der Wal AC, Koch KT, Ploegmakers JPH, van der Schaaf RJ, Henriques JPS, Baan J Jr., Rittersma SZH, Vis MM, Piek JJ, Tijssen JGP, and de Winter RJ
- Published
- 2008
8. Long-term impact of multivessel disease on cause-specific mortality after ST elevation myocardial infarction treated with reperfusion therapy.
- Author
-
van der Schaaf RJ, Timmer JR, Ottervanger JP, Hoorntje JC, de Boer M, Suryapranata H, Zijlstra F, Dambrink JE, van der Schaaf, R J, Timmer, J R, Ottervanger, J P, Hoorntje, J C A, de Boer, M-J, Suryapranata, H, Zijlstra, F, and Dambrink, J-H E
- Abstract
Objectives: To investigate the long-term impact of multivessel coronary artery disease (MVD) on cause-specific mortality in patients with ST elevation myocardial infarction (STEMI) treated with reperfusion therapy.Methods and Results: Patients with STEMI (n = 395) treated with primary angioplasty or thrombolysis in the setting of a randomised clinical trial were enrolled in the study. Follow up was 8 (2) years. For patients who died all available records were reviewed to assess the specific cause of death. MVD was present in 57% of patients. Patients with MVD were older and more of them had diabetes and previous myocardial infarction. Compared with the non-MVD group, residual left ventricular ejection fraction was lower (45.9% v 49.6%, p = 0.001) and total mortality was higher in patients with MVD (32% v 19%, p = 0.002). After adjustment for potential confounders this association was not significant (hazard ratio 1.4, 95% confidence interval (CI) 0.9 to 2.2). When the specific cause of death was considered, sudden death was comparable between patients with and without MVD (10% v 8%, p = 0.49) but death caused by heart failure was significantly higher in patients with MVD (hazard ratio 7.4, 95% CI 1.7 to 32.2).Conclusion: Patients with STEMI and MVD have a higher long-term mortality than do patients with non-MVD. MVD is not an independent predictor of long-term total mortality or sudden death. However, MVD is a very strong and independent predictor of long-term death caused by heart failure. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
9. Time from coronary artery bypass surgery does not affect outcome in patients treated with primary angioplasty for acute saphenous vein graft occlusion.
- Author
-
van der Schaaf RJ, Vis MM, Sjauw KD, Koch KT, Baan J Jr., Tijssen JGP, de Winter RJ, Piek JJ, and Henriques JPS
- Published
- 2007
- Full Text
- View/download PDF
10. Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.
- Author
-
van der Schaaf RJ, Claessen BE, Hoebers LP, Verouden NJ, Koolen JJ, Suttorp MJ, Barbato E, Bax M, Strauss BH, Olivecrona GK, Tuseth V, Glogar D, Råmunddal T, Tijssen JG, Piek JJ, Henriques JP, EXPLORE Investigators, van der Schaaf, René J, Claessen, Bimmer E, and Hoebers, Loes P
- Abstract
Background: In the setting of primary percutaneous coronary intervention, patients with a chronic total occlusion in a non-infarct related artery were recently identified as a high-risk subgroup. It is unclear whether ST-elevation myocardial infarction patients with a chronic total occlusion in a non-infarct related artery should undergo additional percutaneous coronary intervention of the chronic total occlusion on top of optimal medical therapy shortly after primary percutaneous coronary intervention. Possible beneficial effects include reduction in adverse left ventricular remodeling and preservation of global left ventricular function and improved clinical outcome during future coronary events.Methods/design: The Evaluating Xience V and left ventricular function in Percutaneous coronary intervention on occLusiOns afteR ST-Elevation myocardial infarction (EXPLORE) trial is a randomized, prospective, multicenter, two-arm trial with blinded evaluation of endpoints. Three hundred patients after primary percutaneous coronary intervention for ST-elevation myocardial infarction with a chronic total occlusion in a non-infarct related artery are randomized to either elective percutaneous coronary intervention of the chronic total occlusion within seven days or standard medical treatment. When assigned to the invasive arm, an everolimus-eluting coronary stent is used. Primary endpoints are left ventricular ejection fraction and left ventricular end-diastolic volume assessed by cardiac Magnetic Resonance Imaging at four months. Clinical follow-up will continue until five years.Discussion: The ongoing EXPLORE trial is the first randomized clinical trial powered to investigate whether recanalization of a chronic total occlusion in a non-infarct related artery after primary percutaneous coronary intervention for ST-elevation myocardial infarction results in a better preserved residual left ventricular ejection fraction, reduced end-diastolic volume and enhanced clinical outcome.Trial Registration: trialregister.nl NTR1108. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
11. Prognostic value of admission hemoglobin levels in patients presenting with cardiogenic shock.
- Author
-
Vis MM, Sjauw KD, van der Schaaf RJ, Koch KT, Baan J Jr, Tijssen JG, Piek JJ, de Winter RJ, and Henriques JP
- Published
- 2007
- Full Text
- View/download PDF
12. Acute left ventricular dynamic effects of primary percutaneous coronary intervention from occlusion to reperfusion.
- Author
-
Remmelink M, Sjauw KD, Henriques JP, Vis MM, van der Schaaf RJ, Koch KT, Tijssen JG, de Winter RJ, Piek JJ, and Baan J Jr
- Published
- 2009
- Full Text
- View/download PDF
13. Long-Term Survival and Angina After Chronic Total Occlusion Percutaneous Coronary Intervention Compared With Medical Therapy: A Meta-Analysis.
- Author
-
Coerkamp CF, van Veelen A, Mashayekhi KA, Stojkovic SM, Juricic SA, Claessen BEPM, van der Schaaf RJ, Hoebers LPC, Elias J, and Henriques JPS
- Subjects
- Humans, Cardiovascular Agents therapeutic use, Cardiovascular Agents adverse effects, Chronic Disease, Time Factors, Treatment Outcome, Angina Pectoris therapy, Angina Pectoris mortality, Coronary Occlusion mortality, Coronary Occlusion therapy, Percutaneous Coronary Intervention adverse effects
- Published
- 2024
- Full Text
- View/download PDF
14. Vascular response following implantation of the third-generation drug-eluting resorbable coronary magnesium scaffold: an intravascular imaging analysis of the BIOMAG-I first-in-human study.
- Author
-
Seguchi M, Aytekin A, Xhepa E, Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Waksman R, Garcia-Garcia HM, and Joner M
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Neointima, Tissue Scaffolds, Tomography, Optical Coherence methods, Magnesium, Ultrasonography, Interventional methods, Drug-Eluting Stents, Coronary Artery Disease therapy, Coronary Artery Disease diagnostic imaging, Percutaneous Coronary Intervention methods, Percutaneous Coronary Intervention instrumentation, Coronary Vessels diagnostic imaging, Absorbable Implants
- Abstract
Background: The 12-month outcomes of BIOMAG-I - the first-in-human study investigating the third-generation drug-eluting resorbable magnesium scaffold (DREAMS 3G) - showed promising results regarding clinical outcomes and late lumen loss., Aims: The current study aimed to investigate vascular healing parameters assessed by optical coherence tomography (OCT) and intravascular ultrasound (IVUS), focusing on strut visibility, vessel and scaffold areas, and neointimal growth patterns., Methods: This is a BIOMAG-I substudy including patients with available serial OCT and IVUS data. We conducted a frame-based analysis of OCT findings in conjunction with IVUS-derived vessel and scaffold areas, evaluating the qualitative and quantitative aspects of vascular healing., Results: Among the 116 patients enrolled in this trial, 56 patients treated with DREAMS 3G were included in the analysis. At 12 months, OCT imaging revealed that 99.0% of the struts were invisible, and no malapposed struts were depicted. While the vessel area showed no significant difference between the timepoints, the minimum lumen area significantly decreased from post-percutaneous coronary intervention to 6 months (6.88 mm
2 to 4.75 mm2 ; p<0.0001), but no significant changes were observed between 6 and 12 months. Protruding neointimal tissue (PNT) - a unique neointimal presentation observed following resorbable magnesium scaffold implantation - was observed in 89.3% of the study patients at 12 months, and its area exhibited a 47.4% decrease from 6 to 12 months., Conclusions: This imaging substudy revealed that, at 12-month follow-up, virtually all struts of the DREAMS 3G scaffold became invisible, without evident malapposition. The vascular healing response to DREAMS 3G implantation also appeared favourable up to 12 months, which is indicated by advanced strut degradation and spontaneous regressing PNT between 6 and 12 months.- Published
- 2024
- Full Text
- View/download PDF
15. Ten-Year Outcome of Recanalization or Medical Therapy for Concomitant Chronic Total Occlusion After Myocardial Infarction.
- Author
-
van Veelen A, Coerkamp CF, Somsen YBO, Råmunddal T, Ioanes D, Laanmets P, van der Schaaf RJ, Eriksen E, Bax M, Suttorp MJ, Strauss BH, Barbato E, Marques KM, Meuwissen M, Bertrand O, van der Ent M, Knaapen P, Tijssen JGP, Claessen BEPM, Hoebers LPC, Elias J, and Henriques JPS
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Chronic Disease, Time Factors, Follow-Up Studies, Risk Factors, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, Coronary Occlusion therapy, Coronary Occlusion mortality, Coronary Occlusion complications, ST Elevation Myocardial Infarction therapy, ST Elevation Myocardial Infarction mortality, ST Elevation Myocardial Infarction complications
- Abstract
Background: The EXPLORE (Evaluating Xience and Left Ventricular Function in PCI on Occlusions After STEMI) trial was the first and only randomized trial investigating chronic total occlusion (CTO) percutaneous coronary intervention (PCI) early after primary PCI for ST-segment-elevation myocardial infarction, compared with medical therapy for the CTO. We performed a 10-year follow-up of EXPLORE to investigate long-term safety and clinical impact of CTO PCI after ST-segment-elevation myocardial infarction, compared with no-CTO PCI., Methods and Results: In EXPLORE, 302 patients post-ST-segment-elevation myocardial infarction with concurrent CTO were randomized to CTO PCI within ≈1 week or no-CTO PCI. We performed an extended clinical follow-up for the primary end point of major adverse cardiac events, consisting of cardiovascular death, coronary artery bypass grafting, or myocardial infarction. Secondary end points included all-cause death, angina, and dyspnea. Median follow-up was 10 years (interquartile range, 8-11 years). The primary end point occurred in 25% of patients with CTO PCI and in 24% of patients with no-CTO PCI (hazard ratio [HR], 1.11 [95% CI, 0.70-1.76]). Cardiovascular mortality was higher in the CTO PCI group (HR, 2.09 [95% CI, 1.10-2.50]), but all-cause death was similar (HR, 1.53 [95% CI, 0.93-2.50]). Dyspnea relief was more frequent after CTO PCI (83% versus 65%, P =0.005), with no significant difference in angina., Conclusions: This 10-year follow-up of patients post-ST-segment-elevation myocardial infarction randomized to CTO PCI or no-CTO PCI demonstrated no clinical benefit of CTO PCI in major adverse cardiac events or overall mortality. However, CTO PCI was associated with a higher cardiovascular mortality compared with no-CTO PCI. Our long-term data support a careful weighing of effective symptom relief against an elevated cardiovascular mortality risk in CTO PCI decisions., Registration: URL: https://www.trialregister.nl; Unique identifier: NTR1108.
- Published
- 2024
- Full Text
- View/download PDF
16. 5-Year Clinical Outcomes of Paclitaxel-Coated Balloon Angioplasty vs DES in Acute MI: The REVELATION Trial.
- Author
-
Niehe SR, Vos NS, Van Der Schaaf RJ, Amoroso G, Herrman JR, Patterson MS, Slagboom T, and Vink MA
- Subjects
- Humans, Treatment Outcome, Time Factors, Risk Factors, Cardiac Catheters, Percutaneous Coronary Intervention instrumentation, Percutaneous Coronary Intervention adverse effects, Prosthesis Design, Myocardial Infarction therapy, Randomized Controlled Trials as Topic, ST Elevation Myocardial Infarction therapy, ST Elevation Myocardial Infarction diagnostic imaging, Paclitaxel administration & dosage, Angioplasty, Balloon, Coronary instrumentation, Angioplasty, Balloon, Coronary adverse effects, Coated Materials, Biocompatible, Cardiovascular Agents administration & dosage, Cardiovascular Agents adverse effects, Drug-Eluting Stents
- Published
- 2024
- Full Text
- View/download PDF
17. Temporal changes in coronary plaque as assessed by an artificial intelligence-based optical coherence tomography: from the first-in-human trial on DREAMS 3G scaffold.
- Author
-
Garcia-Garcia HM, Waksman R, Melaku GD, Garg M, Beyene S, Wlodarczak A, Kerai A, Levine MB, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, and Haude M
- Subjects
- Humans, Absorbable Implants, Artificial Intelligence, Coronary Angiography, Coronary Vessels, Lipids, Tomography, Optical Coherence methods, Treatment Outcome, Coronary Artery Disease, Drug-Eluting Stents, Percutaneous Coronary Intervention, Plaque, Atherosclerotic
- Abstract
Aims: The aim of the study is to assess the impact of the baseline plaque composition on the DREAMS 3G luminal late loss and to compare the serial plaque changes between baseline and 6 and 12 months (M) follow-up., Methods and Results: A total of 116 patients were enrolled in the BIOMAG-I trial. Patients were imaged with optical coherence tomography (OCT) pre- and post-DREAMS 3G implantation and at 6 and 12 M. OCTPlus software uses artificial intelligence to assess composition (i.e. lipid, calcium, and fibrous tissue) of the plaque. The differences between the OCT-derived minimum lumen area (MLA) post-percutaneous coronary intervention and 12 M were grouped into three terciles. Patients with larger MLA differences at 12 M (P = 0.0003) had significantly larger content of fibrous tissue at baseline. There was a reduction of 24.8% and 20.9% in lipid area, both P < 0.001, between the pre-DREAMS 3G OCT and the 6 and 12 M follow-up. Conversely, the fibrous tissue increased by 48.4% and 36.0% at 6 and 12 M follow-up, both P < 0.001., Conclusion: The larger the fibrous tissue in the lesion at baseline, the larger the luminal loss seen at 6 and 12 M. Following the implantation of DREAMS 3G, favourable healing of the vessel coronary wall occurs as shown by a decrease in the lipid area and an increase in fibrous tissue., Competing Interests: Conflict of interest: H.M.G.-G., R.W., G.D.M., M.G., S.B., A.K., and M.B.L. were core laboratory members, and the remaining authors were investigators of the trial. H.M.G.-G. has grants or contracts from Medtronic, Biotronik, Abbott, Neovasc, Corflow, Alucentbio, Philips, and Chiesi (paid to institution), received consulting fees from Boston Scientific and ACIST, and participates in DSMB/advisory board of the VIVID study. R.W. has grants or contracts from Amgen, Biotronik, Boston Scientific, Medtronic, and Philips IGT; received consulting fees from Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi-Cardia Ltd, Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc, and Venous MedTech; received honoraria from AstraZeneca; participates in DSMB/advisory boards of Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd; and is an investor in MedAlliance and Transmural Systems Inc. J.T. reports grants and contracts from Abbott paid to his institution, speaker honoraria and support for attending meetings from Biotronik, and is an associate editor of Cardiovascular Biologics and Regenerative Medicine and Frontiers in Cardiovascular Medicine. J.E. reports personal fees/speaker honoraria from Abbott, Boston Scientific, Philips, and Shockwave, patents from Shared, and participation in advisory boards of Abbott and Phillips. The institution of J.F.I. receives grants or contracts from Terumo Corp, Biosensors, Concept Medical, Biotronik, Abbott Vascular, and Philips Volcano. J.F.I. reports consulting fees from Biotronik, Medtronic, Cordis, Terumo Corp., and ReCor Medical; speaker fees/honoraria from Terumo Corp, Biosensors, Medalliance, OrbusNeich, Concept Medical, Bristol Myers Squibb/Pfizer, Novartis, Cordis, AstraZeneca, and Philips Volcano; and support to attend meetings from Biotronik and Amgen. The institution of J.B. receives grants or contracts from Shockwave IVLS. J.B. receives consulting fees from Biotronik AG and Boston Scientific and speaker fees/honoraria from Biotronik AG, Boston Scientific, and Abbott Vascular, participates in the DSMB of Boston Scientific, and has a leadership or fiduciary role for Biotronik. G.G.T. reports consulting fees from Biotronik, Medtronic, Abbott, and Terumo and honoraria from Biotronik, Medtronic, Abbott, and Terumo. M.J. reports grant support from Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, and Infraredx; consulting fees from AlchiMedics SAS, Biotronik, TriCares, Veryan, and Shockwave; speaker fees/honoraria from Abbott Vascular, Biotronik, Boston Scientific, Edwards Lifesciences, Cardiac Dimensions, AstraZeneca, Recor Medical, and Shockwave; travel support from SIS Medical, Edwards Lifesciences, Boston Scientific, and Cardiac Dimensions; and participation in Steering Committees of Biotronik and Edwards Lifesciences. R.T. reports lecture fees from Biotronik. M.W. reports speaker honoraria and conference attendance support from Biotronik. G.O. reports lecturer honoraria from Abbott Vascular, Biotronik, and Cordis and is a DSMB member of the SCIENCE trial and a CEC-member of the BIOFREEDOM STEMI trial. M.H. reports grants/contracts from Biotronik, Cardiac Dimensions, OrbusNeich, and Philips; consulting fees from Biotronik, Cardiac Dimensions, Shockwave Medical, and OrbusNeich; honoraria/speaker fees from Biotronik, Cardiac Dimensions, Shockwave Medical, OrbusNeich, and Philips; and support to attend meetings/travel support from Biotronik, is a steering committee member of the BIOSOLVE and BIOMAG trials, and is a past president of EAPCI. All other authors have no conflict of interest to declare., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
18. Less bleeding by omitting aspirin in non-ST-segment elevation acute coronary syndrome patients: Rationale and design of the LEGACY study.
- Author
-
van der Sangen NMR, Küçük IT, Sivanesan S, Appelman Y, Ten Berg JM, Verburg A, Azzahhafi J, Arkenbout EK, Kikkert WJ, Pisters R, Jukema JW, Arslan F, van 't Hof A, Ilhan M, Hoebers LP, van der Schaaf RJ, Damman P, Woudstra P, van de Hoef TP, Bax M, Anthonio RL, Polad J, Adriaenssens T, Dewilde W, Zivelonghi C, Laanmets P, Majas R, Dijkgraaf MGW, Claessen BEPM, and Henriques JPS
- Subjects
- Humans, Aspirin, Platelet Aggregation Inhibitors adverse effects, Drug Therapy, Combination, Hemorrhage chemically induced, Treatment Outcome, Acute Coronary Syndrome drug therapy, Acute Coronary Syndrome surgery, Percutaneous Coronary Intervention methods
- Abstract
Background: Early aspirin withdrawal, also known as P2Y
12 -inhibitor monotherapy, following percutaneous coronary intervention (PCI) for non-ST-segment elevation acute coronary syndrome (NSTE-ACS) can reduce bleeding without a trade-off in efficacy. Still the average daily bleeding risk is highest during the first months and it remains unclear if aspirin can be omitted immediately following PCI., Methods: The LEGACY study is an open-label, multicenter randomized controlled trial evaluating the safety and efficacy of immediate P2Y12 -inhibitor monotherapy versus dual antiplatelet therapy (DAPT) for 12 months in 3,090 patients. Patients are randomized immediately following successful PCI for NSTE-ACS to 75-100 mg aspirin once daily versus no aspirin. The primary hypothesis is that immediately omitting aspirin is superior to DAPT with respect to major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3, or 5 bleeding, while maintaining noninferiority for the composite of all-cause mortality, myocardial infarction and stroke compared to DAPT., Conclusions: The LEGACY study is the first randomized study that is specifically designed to evaluate the impact of immediately omitting aspirin, and thus treating patients with P2Y12 -inhibitor monotherapy, as compared to DAPT for 12 months on bleeding and ischemic events within 12 months following PCI for NSTE-ACS., Competing Interests: Disclosures Dr. Yolande Appelman has received a research grant from the Dutch Heart Foundation. Prof. dr. Jurriën M. ten Berg has received research grants from the ZonMw and speaker fees from Accumetrics, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo, Eli Lilly, Ferrer, the Medicines Company and Pfizer. Dr. Peter Damman has received a research grant from AstraZeneca. Dr. Tim P. van de Hoef has received research grants and speaker fees and from Abbott and Philips. Dr. Bimmer E.P.M. Claessen has received speaker fees from Abiomed and consultancy fees from Amgen, Sanofi, Boston Scientific and Philips. Prof. dr. José P.S. Henriques has received research grants from Abbott Vascular, AstraZeneca, B. Braun, Getinge, Ferrer, Infraredx and ZonMw. All other authors have no relationships with industry to disclose., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
19. EXpansion of stents after intravascular lithoTripsy versus conventional predilatation in CALCified coronary arteries.
- Author
-
Oomens T, Vos NS, van der Schaaf RJ, Amoroso G, Ewing MM, Patterson MS, Herrman JR, Slagboom T, and Vink MA
- Subjects
- Humans, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Coronary Vessels pathology, Prospective Studies, Treatment Outcome, Stents, Percutaneous Coronary Intervention adverse effects, Vascular Calcification diagnostic imaging, Vascular Calcification surgery, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Lithotripsy adverse effects, Lithotripsy methods
- Abstract
Background: Coronary artery calcification is a strong predictor for procedural failure and is independently associated with adverse events after percutaneous coronary intervention (PCI). An important contributor to the impaired outcome is the inability to achieve optimal results due to stent underexpansion or stent deformation/fracture. Intravascular lithotripsy (IVL) has emerged as an alternative technique to change the integrity of calcified plaques., Aims: Our aim was to investigate if pre-treatment with IVL in severely calcified lesions increases stent expansion, assessed by optical coherence tomography (OCT), when compared to predilatation with conventional and/or specialty balloon strategy., Methods: EXIT-CALC was a prospective, single-centre, randomised controlled study. Patients with an indication for PCI and severe calcification of the target lesion were allocated to predilatation with conventional angioplasty balloons or pre-treatment with IVL, followed by drug-eluting stenting and mandatory postdilatation. Primary endpoint was stent expansion assessed by OCT. Secondary endpoints were the occurrence of peri-procedural events and major adverse cardiac events (MACE) in hospital and during follow-up., Results: A total of 40 patients were included. The minimal stent expansion in the IVL-group (n = 19) was 83.9 ± 10.3% and 82.2 ± 11.5% in the conventional group (n = 21) (p = 0.630). Minimal stent area was 6.6 ± 1.5 mm
2 and 6.2 ± 1.8 mm2 , respectively (p = 0.406). No peri-procedural, in-hospital and 30-day follow-up MACE were reported., Conclusions: In severely calcified coronary lesions we found no significant difference in stent expansion measured by OCT when comparing IVL, as plaque modification, with conventional and/or specialty angioplasty balloons., Competing Interests: Declaration of Competing Interest All authors declare that they have no conflicts of interest., (Copyright © 2023. Published by Elsevier B.V.)- Published
- 2023
- Full Text
- View/download PDF
20. A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.
- Author
-
Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth GG, Joner M, Toelg R, Wiemer M, Olivecrano G, Vermeersch P, Garcia-Garcia HM, and Waksman R
- Subjects
- Humans, Absorbable Implants, Coronary Angiography methods, Magnesium therapeutic use, Prospective Studies, Treatment Outcome, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention
- Abstract
Background: The third-generation coronary sirolimus-eluting magnesium scaffold, DREAMS 3G, is a further development of the DREAMS 2G (commercial name Magmaris), aiming to provide performance outcomes similar to drug-eluting stents (DES)., Aims: The BIOMAG-I study aims to assess the safety and performance of this new-generation scaffold., Methods: This is a prospective, multicentre, first-in-human study with clinical and imaging follow-up scheduled at 6 and 12 months. The clinical follow-up will continue for 5 years., Results: A total of 116 patients with 117 lesions were enrolled. At 12 months, after completion of resorption, in-scaffold late lumen loss was 0.24±0.36 mm (median 0.19, interquartile range 0.06-0.36). The minimum lumen area was 4.95±2.24 mm² by intravascular ultrasound and 4.68±2.32 mm² by optical coherence tomography. Three target lesion failures were reported (2.6%, 95% confidence interval: 0.9-7.9), all clinically driven target lesion revascularisations. Cardiac death, target vessel myocardial infarction and definite or probable scaffold thrombosis were absent., Conclusions: Data at the end of the resorption period of DREAMS 3G showed that the third-generation bioresorbable magnesium scaffold is clinically safe and effective, making it a possible alternative to DES., Clinicaltrials: gov: NCT04157153.
- Published
- 2023
- Full Text
- View/download PDF
21. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study.
- Author
-
Haude M, Wlodarczak A, van der Schaaf RJ, Torzewski J, Ferdinande B, Escaned J, Iglesias JF, Bennett J, Toth G, Joner M, Toelg R, Wiemer M, Olivecrona G, Vermeersch P, Garcia-Garcia HM, and Waksman R
- Abstract
Background: A third-generation coronary drug-eluting resorbable magnesium scaffold (DREAMS 3G) was developed to enhance the performance of previous scaffold generations and achieve angiographic outcomes comparable to those of contemporary drug-eluting stents., Methods: This prospective, multicenter, non-randomized, first-in-human study was conducted at 14 centers in Europe. Eligible patients had stable or unstable angina, documented silent ischemia, or non-ST-elevation myocardial infarction, and a maximum of two single de novo lesions in two separate coronary arteries with a reference vessel diameter between 2.5 mm and 4.2 mm. Clinical follow-up was scheduled at one, six and 12 months and annually thereafter until five years. Invasive imaging assessments were scheduled six and 12 months postoperatively. The primary endpoint was angiographic in-scaffold late lumen loss at six months. This trial was registered at ClinicalTrials.gov (NCT04157153)., Findings: Between April 2020 and February 2022, 116 patients with 117 coronary artery lesions were enrolled. At six months, in-scaffold late lumen loss was 0.21 mm (SD 0.31). Intravascular ultrasound assessment showed preservation of the scaffold area (mean 7.59 mm
2 [SD 2.21] post-procedure vs 6.96 mm2 [SD 2.48]) at six months) with a low mean neointimal area (0.02 mm2 [SD 0.10]). Optical coherence tomography revealed that struts were embedded in the vessel wall and were already hardly discernible at six months. Target lesion failure occurred in one (0.9%) patient; a clinically driven target lesion revascularization was performed on post-procedure day 166. No definite or probable scaffold thrombosis or myocardial infarction was observed., Interpretation: These findings show that the implantation of DREAMS 3G in de novo coronary lesions is associated with favorable safety and performance outcomes, comparable to contemporary drug-eluting stents., Funding: This study was funded by BIOTRONIK AG., Competing Interests: MH reports grants/contracts from Biotronik, Cardiac Dimensions, Orbus Neich and Philips, consulting fees from Biotronik, Cardiac Dimensions, and Obrus Neich, honoraria/speaker fees from Biotronik, Cardiac Dimensions, Orbus Neich and Philips, support to attend meetings/travel support from Biotronik, is a steering committee member of the BIOSOLVE and BIOMAG trials, and is a past president of EAPCI. JT reports speaker honoraria and support for attending meetings from Biotronik, and is an associated editor of Cardiovascular Biologics and Regenerative Medicine, JE reports speaker honoraria from Abbott, Boston Scientific, Philips and Shockwave and participation in advisory boards of Abbott, Phillips and Shockwave, the institution of JI receives grants or contracts from Terumo Corp, Biosensors, Concept Medical, Biotronik, Abbott Vascular, Philips Volcano, JI reports consulting fees from Biotronik, Medtronic, Cordis, and Terumo Corp and speaker fees from Terumo Corp, Biosensors, Medalliance, Orbus Neich, Concept Medical, Bristol Myers Squibb/Pfizer, Novartis, Cordis, AstraZeneca, and Philips Volcano, and support to attend meetings from Biotronik and Amgen, the institution of JB receives grants or contracts from Shockwave IVLS, receives consulting fees from Biotronik AG and Boston Scientific, speaker fees from Biotronik AG, Boston Scientific and Abbott Vascular, JB participates in the DSMB of Boston Scientific and has a leadership or fiduciary role for Biotronik, MJ reports grant support from Boston Scientific, Cardiac Dimensions, Edwards LifeSciences and Infraredx, consulting fees from Biotronik, TriCares, Veryan and Shockwave, speaker fees/honoraria from Abbott Vascular, Biotronik, Boston Scientific, Edwards LifeSciences, Cardiac Dimensions, AstraZeneca, Recor Medical, and Shockwave, travel support from SIS Medical, Edwards Lifesciences, Boston Scientific and Cardiac Dimensions, and participation in Steering Committees of Biotronik and Edwards Lifesciences, MW reports speaker honoraria and conference attendance support from Biotronik, GO reports lecturer honoraria from Abbott Vascular, Biotronik and Cordis and is a DSMB member of the SCIENCE trial and a CEC-member of the BIOFREEDOM STEMI trial, HGG has grants or contracts from Medtronic, Biotronik, Abbott, Neovasc, Corflow, Alucentbio, Philips, Chiesi (paid to institution), received consulting fees from Boston Scientific and ACIST, participates in DSMB/advisory board of the VIVID study, RW has grants or contracts from Astra Zeneca, Biotronik, Boston Scientific, Chiesi, Medtronic, and Philips IGT, and received consulting fees from Abbott Vascular, Biotronik, Boston Scientific, Cordis, Medtronic, Philips IGT, Pi. Cardia Ltd, Swiss Interventional Systems/SIS Medical AG, Transmural Systems Inc, andVenous MedTech, receives honoraria from AstraZeneca, participates in DSMB/advisory boards of Abbott Vascular, Boston Scientific, Medtronic, Philips IGT, and Pi-Cardia Ltd, and is an investor from MedAlliance and Transmural Systems Inc. All other authors have no conflict of interest to declare., (© 2023 The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
22. Very Long-Term Outcome of the PRISON-IV Trial: 5-Year Clinical Follow-Up of Ultra-Thin Struts in CTO-PCI.
- Author
-
Wilgenhof A, Zivelonghi C, Teeuwen K, van der Schaaf RJ, Henriques JPS, Vermeersch PHMJ, Bosschaert MAR, Agostoni P, and Suttorp MJ
- Subjects
- Humans, Follow-Up Studies, Prisons, Treatment Outcome, Chronic Disease, Risk Factors, Coronary Angiography, Percutaneous Coronary Intervention adverse effects, Myocardial Infarction, Coronary Occlusion diagnostic imaging, Coronary Occlusion surgery
- Abstract
Competing Interests: Declaration of competing interest The authors have no relationships relevant to the contents of this paper to disclose.
- Published
- 2023
- Full Text
- View/download PDF
23. Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
- Author
-
Kerkmeijer LSM, Renkens MPL, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Garcia-Garcia HM, Kraak R, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, and Wykrzykowska JJ
- Subjects
- Absorbable Implants, Everolimus, Humans, Prosthesis Design, Stents, Treatment Outcome, Coronary Artery Disease surgery, Drug-Eluting Stents, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: Absorb bioresorbable vascular scaffold (BVS)-related events have been reported between 1 and 3 years - the period of active scaffold bioresorption. Data on the performance of the Absorb BVS in daily clinical practice beyond this time point are scarce., Aims: This report aimed to provide the final five-year clinical follow-up of the Absorb BVS in comparison with the XIENCE everolimus-eluting stent (EES). In addition, we evaluated the effect of prolonged dual antiplatelet therapy (DAPT) administration on events in the scaffold group., Methods: AIDA was a multicentre, investigator-initiated, non-inferiority trial, in which 1,845 unselected patients with coronary artery disease were randomly assigned to either the Absorb BVS (n=924) or the XIENCE EES (n=921). Target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction or target vessel revascularisation, was the primary endpoint. Scaffold thrombosis cases were matched with controls and tested for the effect of prolonged DAPT., Results: Up to five-year follow-up, there was no difference in TVF between the Absorb BVS (17.7%) and the XIENCE EES (16.1%) (hazard ratio [HR] 1.31, 95% confidence interval [CI]: 0.90-1.41; p=0.302). Definite or probable device thrombosis (DT) occurred in 43 patients (4.8%) in the scaffold group compared to 13 patients (1.5%) in the stent group (HR 3.32, 95% CI: 1.78-6.17; p<0.001). DT between 3 and 4 years occurred six times in the Absorb arm versus three times in the XIENCE arm. Between 4 and 5 years, the incidence was three versus two, respectively. Of those three DT in the scaffold group, two occurred in XIENCE EES-treated lesions. The odds ratio of scaffold thrombosis in patients on DAPT compared to off DAPT throughout five-year follow-up was 0.36 (95% CI: 0.15-0.86)., Conclusions: The excess risk of the Absorb BVS on late adverse events, in particular device thrombosis, in routine PCI continues up to 4 years and seems to plateau afterwards. Clinical Trial Registration ClinicalTrials.gov: NCT01858077.
- Published
- 2022
- Full Text
- View/download PDF
24. Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion.
- Author
-
van Veelen A, Elias J, van Dongen IM, Hoebers LPC, Claessen BEPM, Ramunddal T, Laanmets P, Eriksen E, van der Schaaf RJ, Nijveldt R, Henriques JPS, and Hirsch A
- Subjects
- Humans, Predictive Value of Tests, Ventricular Function, Right, Coronary Occlusion complications, Coronary Occlusion diagnostic imaging, Coronary Occlusion therapy, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods, ST Elevation Myocardial Infarction complications, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction therapy
- Abstract
The right ventricle (RV) is frequently involved in ST-segment elevation myocardial infarction (STEMI) when the culprit or concurrent chronic total occlusion (CTO) is located in the right coronary artery (RCA). We investigated RV function recovery in STEMI-patients with concurrent CTO. In EXPLORE, STEMI-patients with concurrent CTO were randomized to CTO percutaneous coronary intervention (PCI) or no CTO-PCI. We analyzed 174 EXPLORE patients with serial cardiovascular magnetic resonance imaging RV data (baseline and 4-month follow-up), divided into three groups: CTO-RCA (CTO in RCA, culprit in non-RCA; n = 89), IRA-RCA (infarct related artery [IRA] in RCA, CTO in non-RCA; n = 56), and no-RCA (culprit and CTO not in RCA; n = 29). Tricuspid annular plane systolic excursion (TAPSE), RV ejection fraction (RVEF), RV global longitudinal strain (GLS) and free wall longitudinal strain (FWLS) were measured. We found that RV strain and TAPSE improved in IRA-RCA and CTO-RCA (irrespective of CTO-PCI) at follow-up, but not in no-RCA. Only RV FWLS was different among groups at baseline, which was lower in IRA-RCA than no-RCA (- 26.0 ± 8.3% versus - 31.0 ± 6.4%, p = 0.006). Baseline RVEF, RV end-diastolic volume and TAPSE were associated with RVEF at 4 months. RV function parameters were not predictive of 4 year mortality, although RV GLS showed additional predictive value for New York Heart Association Classification > 1 at 4 months. In conclusion, RV parameters significantly improved in patients with acute or chronic RCA occlusion, but not in no-RCA patients. RV FWLS was the only RV parameter able to discriminate between acute ischemic and non-ischemic myocardium. Moreover, RV GLS was independently predictive for functional status., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
25. Pronounced late acquired focal coronary artery dilatation after paclitaxel-coated balloon angioplasty: observations from the randomized REVascularization With PaclitaxEL-Coated Balloon Angioplasty Versus Drug-Eluting Stenting in Acute Myocardial InfarcTION (REVELATION) trial.
- Author
-
Vos NS, Amoroso G, Herrman JR, Patterson MS, van der Schaaf RJ, Slagboom T, and Vink MA
- Subjects
- Aged, Angioplasty, Balloon, Coronary methods, Angioplasty, Balloon, Coronary statistics & numerical data, Coronary Vessels diagnostic imaging, Drug-Eluting Stents standards, Drug-Eluting Stents statistics & numerical data, Female, Humans, Male, Middle Aged, Myocardial Infarction physiopathology, Paclitaxel therapeutic use, Treatment Outcome, Coronary Vessels physiopathology, Myocardial Infarction therapy, Paclitaxel pharmacology
- Published
- 2022
- Full Text
- View/download PDF
26. Extremity Dysfunction After Large-Bore Radial and Femoral Arterial Access.
- Author
-
Meijers TA, Aminian A, van Wely M, Teeuwen K, Schmitz T, Dirksen MT, Rathore S, van der Schaaf RJ, Knaapen P, Dens J, Iglesias JF, Agostoni P, Roolvink V, Lemmert ME, Hermanides RS, van Royen N, and van Leeuwen MAH
- Subjects
- Female, Femoral Artery, Humans, Lower Extremity, Pain etiology, Radial Artery, Treatment Outcome, Upper Extremity, Catheterization, Peripheral adverse effects, Catheterization, Peripheral methods, Percutaneous Coronary Intervention adverse effects, Percutaneous Coronary Intervention methods
- Abstract
Background The use of large-bore (LB) arterial access and guiding catheters has been advocated for complex percutaneous coronary intervention. However, the impact of LB transradial access (TRA) and transfemoral access (TFA) on extremity dysfunction is currently unknown. Methods and Results The predefined substudy of the COLOR (Complex Large-Bore Radial PCI) trial aimed to assess upper and lower-extremity dysfunction after LB radial and femoral access. Upper-extremity function was assessed in LB TRA-treated patients by the Quick Disabilities of the Arm, Shoulder, and Hand questionnaire and lower-extremity function in LB TFA-treated patients by the Lower Extremity Functional Scale questionnaire. Extremity pain and effect of access site complications and risk factors on extremity dysfunction was also analyzed. There were 343 patients who completed analyzable questionnaires. Overall, upper and lower-extremity function did not decrease over time when LB TRA and TFA were used for complex percutaneous coronary intervention, as represented by the median Quick Disabilities of the Arm, Shoulder, and Hand score (6.8 at baseline and 2.1 at follow-up, higher is worse) and Lower Extremity Functional Scale score (56 at baseline and 58 at follow-up, lower is worse). Clinically relevant extremity dysfunction occurred in 6% after TRA and 9% after TFA. A trend for more pronounced upper-limb dysfunction was present in female patients after LB TRA ( P =0.05). Lower-extremity pain at discharge was significantly higher in patients with femoral access site complications ( P =0.02). Conclusions Following LB TRA and TFA, self-reported upper and lower-limb function did not decrease over time in the majority of patients. Clinically relevant limb dysfunction occurs in a small minority of patients regardless of radial or femoral access. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03846752.
- Published
- 2022
- Full Text
- View/download PDF
27. Two-Year Clinical Outcomes of the REVELATION Study: Sustained Safety and Feasibility of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction.
- Author
-
Niehe SR, Vos NS, Van Der Schaaf RJ, Amoroso G, Herrman JR, Patterson MS, Slagboom T, and Vink MA
- Subjects
- Coated Materials, Biocompatible, Feasibility Studies, Humans, Paclitaxel, Treatment Outcome, Angioplasty, Balloon, Coronary, Drug-Eluting Stents adverse effects, Fractional Flow Reserve, Myocardial, Myocardial Infarction diagnosis, Myocardial Infarction surgery
- Abstract
Objectives: The randomized REVELATION (REVascularization With PaclitaxEL-Coated Balloon Angioplasty Versus Drug-Eluting Stenting in Acute Myocardial InfarcTION) trial showed that in the setting of ST-segment elevation myocardial infarction (STEMI), a drug-coated balloon (DCB) strategy was non-inferior to a drug-eluting stent (DES) strategy in terms of fractional flow reserve assessed at 9 months. The aim of the present study is to evaluate the long-term clinical outcome of this treatment strategy., Methods: Between October 2014 and November 2017, a total of 120 patients with a non-severely calcified culprit lesion in a native coronary artery and a residual stenosis of <50% after predilation were randomized to treatment with DCB or DES. Primary clinical endpoint was the occurrence of major adverse cardiac events, defined as death, recurrent myocardial infarction, or target-lesion revascularization, the occurrence of definite ST, and non-coronary artery bypass grafting (CABG) major bleeding., Results: Complete clinical follow-up at 2 years was available for 109 patients (91%). A major adverse cardiac event occurred in 3 patients (5.4%) in the DCB group and 1 patient (1.9%) in the DES group (hazard ratio, 2.86; 95% confidence interval, 0.30-27.53; P=.34). Between 9 months and 2 years, only 1 additional event occurred (target-lesion revascularization in a patient randomized to DCB)., Conclusion: In this randomized study of DCB vs DES in selected patients presenting with STEMI, 2-year clinical outcome was excellent and comparable between the DCB and DES groups.
- Published
- 2022
- Full Text
- View/download PDF
28. One-year mortality in NSTEMI patients is unaffected by timing of PCI within the first week of admission: Results of a real-world cohort analysis.
- Author
-
Fagel ND, Amoroso G, Rabbering T, Gescher F, Vink MA, Slagboom T, van der Schaaf RJ, Herrman JR, Patterson MS, Vos NS, Verbeek EC, de Winter RJ, and Riezebos RK
- Subjects
- Cohort Studies, Humans, Retrospective Studies, Treatment Outcome, Non-ST Elevated Myocardial Infarction diagnostic imaging, Non-ST Elevated Myocardial Infarction therapy, Percutaneous Coronary Intervention
- Abstract
Objectives: We aimed to explore the impact of time to percutaneous coronary intervention (PCI) (T2P) on 1-year mortality in non-ST-elevation myocardial infarction (NSTEMI) patients., Background: The current guidelines recommend an early invasive strategy for NSTEMI patients. However, impact of an early invasive strategy on mortality is a matter of debate. For that reason, real world data are of great value to determine the optimal treatment window., Methods: This retrospective single center cohort study was performed in a high-volume PCI center in Amsterdam, The Netherlands. Intermediate- and high-risk NSTEMI patients undergoing PCI were included. The main discriminant was timing of PCI after admission (T2P), stratified according to different time windows (<24 h, 24-72 h, 72 h-7 days or >7 days). We analyzed 1-year mortality and the time distribution of overall survival., Results: In total, 848 patients treated between January 1, 2016 and January 1, 2018 were included in the analysis. T2P was <24 h in 145 patients, 24-72 h in 192 patients, 72 h-7 days in 275 patients, and >7 days in 236 patients. The mean GRACE-risk score was 127.1 (SD 28.7), 130.0 (33.1), 133.8 (32.1), and 148.7 (34.6) respectively, p = <0.001. After adjusting for confounders, 1-year mortality in patients with T2P <24 h did not significantly differ when compared with T2P 24-72 h (OR = 1.08; 95% CI = 0.33-3.51) and T2P 72 h-7 days (OR 1.72; 95% CI = 0.57-5.21) but was significantly higher in T2P >7 days (OR = 3.20; 95% CI = 1.06-9.68)., Conclusions: In an unselected cohort of patients with NSTEMI, treatment by PCI <24 h did not lead to improved survival as compared to aT2P <7 days strategy. Delay in PCI >7 days after admission resulted in worse outcome., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
29. Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
- Author
-
Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Kraak RP, Onuma Y, Serruys PW, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, and Wykrzykowska JJ
- Subjects
- Absorbable Implants, Everolimus adverse effects, Humans, Prosthesis Design, Risk Factors, Stents, Time Factors, Treatment Outcome, Cardiovascular Agents adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease therapy, Diabetes Mellitus diagnosis, Drug-Eluting Stents, Percutaneous Coronary Intervention adverse effects
- Abstract
Background: In this prespecified AIDA-trial sub-study we investigate the clinical performance of absorb bioresorbable vascular scaffold (BVS) compared to Xience everolimus-eluting stent (EES) in routine percutaneous coronary intervention (PCI) in patients with diabetes mellitus (DM) at complete 3-year follow-up., Methods and Results: All 1,845 randomized patients were subdivided by medical history with DM or without DM. Of the 924 Absorb BVS patients, 171 (18.5%) patients had DM, of which 65 (38.0%) were treated with insulin (iTDM). Of the 921 Xience EES patients, 153 (16.6%) patients had DM, of which 45 (29.4%) were insulin-treated diabetes mellitus (iTDM). Target vessel failure (TVF), composite of cardiac death, target vessel myocardial infarction, and target vessel revascularization, occurred in 18.7% of diabetic patients treated with Absorb patients versus in 18.0% patients treated with Xience EES (p = .840). In nondiabetics the rates of TVF were 12.3% in Absorb BVS versus 11.0% in Xience EES (p = .391). Definite/probable device thrombosis occurred more frequently in Absorb BVS compared to Xience EES in both diabetic and nondiabetic patients (4.8% versus 0.7%; p = .028 and 3.2% vs. 0.5%; p < .001, respectively)., Conclusions: In routine PCI practice, both Absorb BVS and Xience EES have worse clinical outcomes in diabetic patients as compared to nondiabetic patients. Throughout all clinical presentations, Absorb BVS was associated with higher rates of device thrombosis at 3-year follow-up., (© 2020 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
30. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial.
- Author
-
Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WAW, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van't Hof AWJ, Lee SWL, Roolvink V, Ligtenberg E, Postma S, Kolkman EJJ, Brouwer MA, Kedhi E, and De Luca G
- Subjects
- Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage chemically induced, Humans, Male, Platelet Aggregation Inhibitors therapeutic use, Prospective Studies, Sex Factors, Stents, Stroke, Thrombosis, Treatment Outcome, Acute Coronary Syndrome drug therapy, Percutaneous Coronary Intervention
- Abstract
Background: Gender differences in the thrombotic and bleeding risk have been suggested to condition the benefits of antithrombotic therapies in Acute Coronary Syndrome (ACS) patients, and mainly among those undergoing percutaneous coronary interventions with drug eluting stents (DES). The impact of gender on the optimal duration of dual antiplatelet therapy (DAPT) in ACS patients is still unexplored and was, therefore, the aim of the present sub-study., Methods: REDUCE was a prospective, multicenter, randomized investigator-initiated study designed to enroll 1500 ACS patients after treatment with the COMBO Dual Stent Therapy, based on a noninferiority design. Patients were randomized in a 1:1 fashion to either 3 or 12 months of DAPT. Primary study endpoint was a composite of all-cause mortality, myocardial infarction, definite/probable stent thrombosis (ST), stroke, target-vessel revascularization (TVR) and bleedings (BARC II, III, V) at 12 months. Secondary endpoints were cardiovascular mortality and the individual components of the primary endpoint within 24 months., Results: From June 2014 to May 2016 300 women and 1196 men were included in the study. Among them, 43.7% of females and 51.9% of males were assigned to the 3 months DAPT treatment. Baseline characteristics were well matched between the two arms, with the exception of a lower rate of TIMI flow < 3 (p = 0.04), lower systolic blood pressure (p = 0.05) and use of spironolactone (p = 0.006) among women and a more advanced age (p = 0.05) among men receiving a short-term DAPT. At a mean follow-up of 525 (± 198) days, no difference in the primary endpoint was observed according to DAPT duration in both females [6.9% vs 5.9%, HR (95% CI) = 1.19 (0.48-2.9), p = 0.71] and males [8.2% vs 9%, HR (95% CI) = 0.92 (0.63-1.35), p = 0.67; p INT = 0.20]. Results were confirmed after correction for baseline differences [females: adjusted HR (95% CI) = 1.12 (0.45-2.78), p = 0.81; males: adjusted HR (95% CI) = 0.90 (0.61-1.32), p = 0.60]. Comparable rates of survival, thrombotic (MI, stent thrombosis, TVR, stroke) and bleeding events were observed with the two DAPT strategies, with no impact of gender., Conclusions: The present study shows that among ACS patients randomized in the REDUCE trial, a 3 months DAPT strategy offers comparable results as compared to a standard 12 months DAPT at 2-years follow-up in both male and female gender., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
31. Randomized Comparison Between Radial and Femoral Large-Bore Access for Complex Percutaneous Coronary Intervention.
- Author
-
Meijers TA, Aminian A, van Wely M, Teeuwen K, Schmitz T, Dirksen MT, Rathore S, van der Schaaf RJ, Knaapen P, Dens J, Iglesias JF, Agostoni P, Roolvink V, Hermanides RS, van Royen N, and van Leeuwen MAH
- Subjects
- Femoral Artery diagnostic imaging, Humans, Prospective Studies, Radial Artery diagnostic imaging, Treatment Outcome, Percutaneous Coronary Intervention adverse effects
- Abstract
Objectives: The aim of this study was to investigate whether transradial (TR) percutaneous coronary intervention (PCI) is superior to transfemoral (TF) PCI in complex coronary lesions with large-bore guiding catheters with respect to clinically relevant access site-related bleeding or vascular complications., Background: The femoral artery is currently the most applied access site for PCI of complex coronary lesions, especially when large-bore guiding catheters are required. With downsizing of TR equipment, TR PCI may be increasingly applied in these patients and might be a safer alternative compared with the TF approach., Methods: An international prospective multicenter trial was conducted, randomizing 388 patients with planned PCI for complex coronary lesions, including chronic total occlusion, left main, heavy calcification, or complex bifurcation, to either 7-F TR access (TRA) or 7-F TF access (TFA). The primary endpoint was defined as access site-related clinically significant bleeding or vascular complications requiring intervention at discharge. The secondary endpoint was procedural success., Results: The primary endpoint event rate was 3.6% for TRA and 19.1% for TFA (p < 0.001). The crossover rate from radial to femoral access was 3.6% and from femoral to radial access was 2.6% (p = 0.558). The procedural success rate was 89.2% for TFA and 86.0% for TRA (p = 0.285). There was no difference between TFA and TRA with regard to procedural duration, contrast volume, or radiation dose., Conclusions: In patients undergoing PCI of complex coronary lesions with large-bore access, radial compared with femoral access is associated with a significant reduction in clinically relevant access-site bleeding or vascular complications, without affecting procedural success. (Complex Large-Bore Radial Percutaneous Coronary Intervention [PCI] Trial [Color]; NCT03846752)., Competing Interests: Funding Support and Author Disclosures Terumo EMEA supported this investigator-initiated study with an unrestricted grant. Drs. van Leeuwen, Aminian, Dens, and Iglesias are consultants for Terumo. Drs. Iglesias and Schmitz have received honoraria and speaker fees from Terumo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
32. Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusion-A subanalysis of the EXPLORE trial.
- Author
-
Kolk MZH, van Veelen A, Agostoni P, van Houwelingen GK, Ouweneel DM, Hoebers LP, Råmunddal T, Laanmets P, Eriksen E, Bax M, Suttorp MJ, Claessen BEPM, van der Schaaf RJ, Elias J, van Dongen IM, and Henriques JPS
- Subjects
- Chronic Disease, Humans, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Coronary Occlusion diagnostic imaging, Coronary Occlusion therapy, Percutaneous Coronary Intervention adverse effects
- Abstract
Objective: To evaluate predictors of procedural success of percutaneous coronary intervention (PCI) of chronic total coronary occlusions (CTOs) in a non-infarct-related artery following ST-segment elevation myocardial infarction (STEMI), and demonstrate the effect on left ventricular functionality (LVF), infarct size (IS), and pro-arrhythmic electrocardiogram (ECG) parameters., Background: Predictors of unsuccessful revascularization of a CTO are numerous, although following STEMI, these are lacking. Besides, effects of failed CTO PCI (FPCI) on the myocardium are unknown., Methods: This is a subanalysis of the EXPLORE trial, in which 302 STEMI patients with a concurrent CTO were randomized to CTO PCI (n = 147) or no-CTO PCI (NPCI, n = 154). For the purpose of this subanalysis, we divided patients into successful CTO PCI (SPCI, n = 106), FPCI (n = 41), and NPCI (n = 154) groups. Cardiac magnetic resonance imaging and angiographic data were derived from the EXPLORE database, combined with ECG parameters. To gain more insight, all outcomes were compared with patients that did not undergo CTO PCI., Results: In multivariate regression, only CTO lesion length >20 mm was an independent predictor of procedural failure (OR 3.31 [1.49-7.39]). No significant differences in median left ventricular ejection fraction, left ventricular end-diastolic volume, IS, and the pro-arrhythmic ECG parameters such as QT-dispersion, QTc-time, and TpTe-intervals were seen between the SPCI and FPCI groups at 4 months follow-up., Conclusion: This subanalysis of the EXPLORE trial has demonstrated that a CTO lesion length >20 mm is an independent predictor of CTO PCI failure, whereas procedural failure did not lead to any adverse effects on LVF nor pro-arrhythmic ECG parameters., (© 2020 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
33. An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: The OPTIMA-2 randomized controlled trial.
- Author
-
Fagel ND, Amoroso G, Vink MA, Slagboom T, van der Schaaf RJ, Herrman JP, Patterson MS, Oosterwerff EFJ, Vos NS, Verheugt FWA, Tijssen JGP, de Winter RJ, and Riezebos RK
- Subjects
- Aged, Area Under Curve, Aspirin adverse effects, Aspirin therapeutic use, Cause of Death, Combined Modality Therapy methods, Creatine Kinase, MB Form blood, Early Termination of Clinical Trials, Factor Xa Inhibitors adverse effects, Factor Xa Inhibitors therapeutic use, Female, Fondaparinux adverse effects, Fondaparinux therapeutic use, Humans, Male, Medical Futility, Non-ST Elevated Myocardial Infarction mortality, Non-ST Elevated Myocardial Infarction pathology, Platelet Aggregation Inhibitors adverse effects, Prospective Studies, Ticagrelor adverse effects, Ticagrelor therapeutic use, Time Factors, Coronary Angiography, Non-ST Elevated Myocardial Infarction diagnostic imaging, Non-ST Elevated Myocardial Infarction therapy, Percutaneous Coronary Intervention methods, Platelet Aggregation Inhibitors therapeutic use
- Abstract
Background: In intermediate- and high-risk non-ST elevated acute coronary syndrome (NSTE-ACS) patients, a routine invasive approach is recommended. The timing of coronary angiography remains controversial. To assess whether an immediate (<3 hours) invasive treatment strategy would reduce infarct size and is safe, compared with an early strategy (12-24 hours), for patients admitted with NSTE-ACS while preferably treated with ticagrelor., Methods: In this single-center, prospective, randomized trial an immediate or early invasive strategy was randomly assigned to patients with NSTE-ACS. At admission, the patients were preferably treated with a combination of aspirin, ticagrelor and fondaparinux. The primary endpoint was the infarct size as measured by area under the curve (AUC) of CK-MB in 48 hours. Secondary endpoints were bleeding outcomes and major adverse cardiac events (MACE): composite of all-cause death, MI and unplanned revascularization. Interim analysis showed futility regarding the primary endpoint and trial inclusion was terminated., Results: In total 249 patients (71% of planned) were included. The primary endpoint of in-hospital infarct size was a median AUC of CK-MB 186.2 ng/mL in the immediate group (IQR 112-618) and 201.3 ng/mL in the early group (IQR 119-479). Clinical follow-up was 1-year. The MACE-rate was 10% in the immediate and 10% in the early group (hazard ratio [HR] 1.13, 95% CI: 0.52-2.49)., Conclusions: In NSTE-ACS patients randomized to either an immediate or an early-invasive strategy the observed median difference in the primary endpoint was about half the magnitude of the expected difference. The trial was terminated early for futility after 71% of the projected enrollment had been randomized into the trial., Competing Interests: Declaration of interest FWAV has received honoraria for consulting and presentations from AstraZeneca. All other authors have no conflicts of interest to declare., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial.
- Author
-
Kedhi E, Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van' T Hof AW, Lee SW, Roolvink V, Ligtenberg E, Postma S, Kolkman EJ, Brouwer MA, Dudek D, and De Luca G
- Subjects
- Aged, Child, Preschool, Drug Therapy, Combination, Follow-Up Studies, Humans, Infant, Male, Platelet Aggregation Inhibitors adverse effects, Prospective Studies, Stents, Treatment Outcome, Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome drug therapy, Drug-Eluting Stents, Percutaneous Coronary Intervention adverse effects
- Abstract
Background and Aims: The impact of advanced age on the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization (PCI) is still greatly debated. Therefore, the aim of the present sub-analysis of the REDUCE trial was to assess the impact of age on the comparison between a short 3 months vs standard 12 months DAPT in ACS patients treated with the COMBO Dual Stent Therapy., Methods: The REDUCE trial is a prospective, multicenter, investigator-initiated study that randomized ACS patients undergoing PCI with the COMBO drug eluting stent to either 3 or 12 months of DAPT. The study population was divided according to age (
- Published
- 2021
- Full Text
- View/download PDF
35. Transulnar coronary intervention complicated by compartment syndrome.
- Author
-
Smits MWL, van der Schaaf RJ, Herrman JP, and Kuipers RS
- Subjects
- Angina Pectoris diagnosis, Biomarkers blood, Compartment Syndromes diagnostic imaging, Diagnosis, Differential, Drug-Eluting Stents, Electrocardiography, Humans, Male, Middle Aged, Suture Techniques, Ultrasonography, Angina Pectoris therapy, Compartment Syndromes etiology, Compartment Syndromes surgery, Percutaneous Coronary Intervention adverse effects, Ulnar Artery
- Abstract
We describe a case of a compartment syndrome after transulnar coronary intervention. As far as we are aware of, this is the first report of such a complication after a transulnar approach described in the literature. Compartment syndrome is a very rare but possibly devastating complication of coronary angiography and percutaneous coronary interventions. We retrospectively observed an incidence rate of 0.007% after 13,948 coronary angiographies or 0.013% after 7532 interventions performed through the wrist in our centre in the last 5 years. Rapid recognition and treatment of this rare complication may prevent long-term morbidity and are thus of utmost importance. General measures should be taken to reduce this incidence of this serious complication., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
36. Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial.
- Author
-
Kraak RP, Tijssen RYG, van Dongen IM, Elias J, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers A, Tijssen JGP, Piek JJ, de Winter RJ, Henriques JPS, and Wykrzykowska JJ
- Subjects
- Absorbable Implants, Everolimus, Humans, Prosthesis Design, Treatment Outcome, Cardiovascular Agents, Coronary Artery Disease, Drug-Eluting Stents, Percutaneous Coronary Intervention
- Abstract
Aims: We aimed to evaluate the impact of the complexity of coronary disease as assessed by the SYNTAX score (SXscore) on the clinical outcomes in the AIDA trial., Methods and Results: In the AIDA trial, we compared Absorb versus XIENCE in routine clinical practice. Clinical outcomes were stratified by SXscore tertiles: SXlow (SXscore ≤8), SXmid (SXscore >8 and ≤15) and SXhigh (>15). The SXscore was available in 1,661 of the 1,845 (90%) patients. The event rate of TVF was numerically lower in Absorb compared to XIENCE (3.7% versus 5.6%; p=0.257) in the SXlow tertile, numerically higher in Absorb in the SXmid tertile (11.4% versus 9.3%, p=0.421) and similar in the SXhigh tertile (15.5% versus 15.6%; p=0.960). The rates of definite/probable device thrombosis in Absorb versus XIENCE were significantly higher in the SXmid tertile (3.3% versus 0.8%, p=0.043) and in the SXhigh tertile (3.7% versus 0.8%, p=0.006)., Conclusions: We found no significantly different rates of TVF between Absorb and XIENCE patients. Absorb-treated patients in the SXmid and SXhigh tertiles had an increased risk of device thrombosis when compared to XIENCE-treated patients. The rates of device thrombosis in the SXlow tertile, while still higher for Absorb, are more acceptable than in the SXmid and SXhigh score tertiles.
- Published
- 2020
- Full Text
- View/download PDF
37. Complex Large-Bore Radial percutaneous coronary intervention: rationale of the COLOR trial study protocol.
- Author
-
Meijers TA, Aminian A, Teeuwen K, van Wely M, Schmitz T, Dirksen MT, van der Schaaf RJ, Iglesias JF, Agostoni P, Dens J, Knaapen P, Rathore S, Ottervanger JP, Dambrink JE, Roolvink V, Gosselink ATM, Hermanides RS, van Royen N, and van Leeuwen MAH
- Subjects
- Coronary Angiography, Femoral Artery surgery, Humans, Japan, Treatment Outcome, Percutaneous Coronary Intervention, Radial Artery surgery
- Abstract
Introduction: The radial artery has become the standard access site for percutaneous coronary intervention (PCI) in stable coronary artery disease and acute coronary syndrome, because of less access site related bleeding complications. Patients with complex coronary lesions are under-represented in randomised trials comparing radial with femoral access with regard to safety and efficacy. The femoral artery is currently the most applied access site in patients with complex coronary lesions, especially when large bore guiding catheters are required. With slender technology, transradial PCI may be increasingly applied in patients with complex coronary lesions when large bore guiding catheters are mandatory and might be a safer alternative as compared with the transfemoral approach., Methods and Analysis: A total of 388 patients undergoing complex PCI will be randomised to radial 7 French access with Terumo Glidesheath Slender (Terumo, Japan) or femoral 7 French access as comparator. The primary outcome is the incidence of the composite end point of clinically relevant access site related bleeding and/or vascular complications requiring intervention. Procedural success and major adverse cardiovascular events up to 1 month will also be compared between both groups., Ethics and Dissemination: Ethical approval for the study was granted by the local Ethics Committee at each recruiting center ('Medisch Ethische Toetsing Commissie Isala Zwolle', 'Commissie voor medische ethiek ZNA', 'Comité Medische Ethiek Ziekenhuis Oost-Limburg', 'Comité d'éthique CHU-Charleroi-ISPPC', 'Commission cantonale d'éthique de la recherche CCER-Republique et Canton de Geneve', 'Ethik Kommission de Ärztekammer Nordrhein' and 'Riverside Research Ethics Committee'). The trial outcomes will be published in peer-reviewed journals of the concerned literature., Trial Registration Number: NCT03846752., Competing Interests: Competing interests: MAHvL, AA and and JFI are consultants for Terumo. JFI and TS have received honoraria/speakers fee for Terumo, the other authors have no conflicts of interest to declare., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
38. The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
- Author
-
Tijssen RYG, Kerkmeijer LSM, Takahashi K, Kogame N, Katagiri Y, Kraak RP, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, and Wykrzykowska JJ
- Subjects
- Angioplasty, Balloon, Coronary adverse effects, Coronary Artery Disease diagnostic imaging, Humans, Myocardial Infarction diagnostic imaging, Myocardial Infarction etiology, Predictive Value of Tests, Prosthesis Design, Risk Factors, Thrombosis diagnostic imaging, Thrombosis etiology, Time Factors, Treatment Outcome, Absorbable Implants, Angioplasty, Balloon, Coronary instrumentation, Coronary Angiography, Coronary Artery Disease therapy, Coronary Vessels diagnostic imaging, Drug-Eluting Stents
- Abstract
It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse events such as target vessel failure and device thrombosis. In this explorative AIDA trial QCA substudy, we sought to investigate the influence of implantation techniques on lesion-oriented outcomes in both the Absorb BVS and Xience EES arm at complete 3-year follow-up. The current analysis includes 2152 study lesions treated with at least one study device, of which the baseline angiogram was suited for offline QCA analysis, including Dmax analysis. The lesion-oriented composite outcome (LOCE) of this analysis was a composite of definite device thrombosis, target lesion revascularization and target-vessel myocardial infarction. In Absorb BVS, the Lesion-oriented composite endpoint (LOCE) occurred numerically less in correctly QCA sized vessels when compared to incorrectly sized vessels 8.5% (58/696) versus 11.1% (39/358), p = 0.151. In Xience EES, LOCE had occurred more frequently in incorrectly sized devices according to device diameter/RVD matching; 2.2% (4/187) in correctly sized devices versus 7.1% (63/911) in incorrectly sized devices (p = 0.014). In this AIDA trial QCA substudy, rates of LOCE were significantly lower in Xience EES treated lesions in which devices were correctly sized according to the definitions of device diameter/RVD matching.
- Published
- 2020
- Full Text
- View/download PDF
39. Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry.
- Author
-
Verheye S, Wlodarczak A, Montorsi P, Bennett J, Torzewski J, Haude M, Vrolix M, Buck T, Aminian A, van der Schaaf RJ, Nuruddin AA, and Lee MKY
- Subjects
- Absorbable Implants, Drug-Eluting Stents, Humans, Metals, Treatment Outcome, Registries
- Published
- 2020
- Full Text
- View/download PDF
40. A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial.
- Author
-
Kerkmeijer LSM, Tijssen RYG, Hofma SH, Pinxterhuis TH, Kraak RP, Kalkman DN, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Beijk MA, Baan J Jr, Vis MM, Koch KT, Tijssen JGP, Piek JJ, Henriques JPS, de Winter RJ, and Wykrzykowska JJ
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Single-Blind Method, Time Factors, Treatment Outcome, Absorbable Implants trends, Bioprosthesis trends, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Sex Characteristics, Tissue Scaffolds trends
- Abstract
Background: Females are underrepresented in clinical trials evaluating new stent technologies whilst results may differ between the sexes. Females are known to have smaller, more tortuous coronary arteries and have generally more comorbidities. On the other hand, they may have smaller plaque burden. This subgroup-analysis sought to assess sex-specific outcomes after Absorb bioresorbable vascular scaffold (BVS) or XIENCE everolimus-eluting stent (EES) implantation., Methods: The AIDA trial was an investigator-initiated, non-inferiority, all-comers trial, in which 1845 patients were randomly assigned to either Absorb BVS or XIENCE EES. Baseline clinical, angiography and procedural variables, as well as 2-year clinical outcomes were analyzed by sex and device modality., Results: Of the 1845 randomized patients, 475 (25.7%) were females. The 2-year rates of target vessel failure (TVF) with Absorb BVS versus XIENCE EES in females were 6.4% versus 10.6% (HR 0.59; 95% CI: 0.31-1.11; p = 0.10) and in males 12.7% versus 9.7% (HR 1.34; 95% CI: 0.98-1.85; p = 0.07). Males treated with Absorb BVS were at higher risk for TVF compared to females treated with Absorb BVS (HR 2.06; 95% CI 1.21-3.53; p = 0.007). Definite/probable device thrombosis occurred in females with Absorb BVS versus XIENCE EES in 1.6% versus 1.4% (HR 1.15; 95% CI: 0.26-5.12; p = 0.86) and in males 3.9% versus 0.7% (HR 5.55; 95% CI: 2.11-14.35; p < 0.001). A statistical significant interaction between sex and device was present for TVF (p = 0.02), but was not seen for definite/probable device thrombosis (p = 0.08)., Conclusions: In this subgroup analysis, Absorb BVS used in routine practice tends to result in better clinical outcomes in females compared to males., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
41. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
- Author
-
Tijssen RYG, van der Schaaf RJ, Kraak RP, Vink MA, Hofma SH, Arkenbout EK, Weevers APJD, Kerkmeijer LSM, Onuma Y, Serruys PW, Beijk MAM, Koch KT, Baan J Jr, Vis MM, Piek JJ, Tijssen JGP, Henriques JPS, de Winter RJ, and Wykrzykowska JJ
- Subjects
- Acute Coronary Syndrome diagnostic imaging, Aged, Cardiovascular Agents adverse effects, Coronary Artery Disease diagnostic imaging, Coronary Thrombosis etiology, Everolimus adverse effects, Female, Humans, Male, Middle Aged, Netherlands, Percutaneous Coronary Intervention adverse effects, Prosthesis Design, Risk Factors, Single-Blind Method, Time Factors, Treatment Outcome, Absorbable Implants, Acute Coronary Syndrome therapy, Cardiovascular Agents administration & dosage, Coronary Artery Disease therapy, Drug-Eluting Stents, Everolimus administration & dosage, Metals, Percutaneous Coronary Intervention instrumentation
- Abstract
Background: Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI), might lead to better outcomes when compared to conventional treatment with metallic drug eluting stents. In this prespecified subgroup analysis of the Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial, we evaluated the clinical outcomes of Absorb bioresorbable vascular scaffold (BVS) versus Xience everolimus eluting stent (EES) treated patients presenting either with or without ACS., Methods and Results: We classified AIDA patients on the basis of clinical presentation of ACS or of no-ACS. The rate of the 2-year primary endpoint of target vessel failure (TVF) was similar after treatment with Absorb BVS or Xience EES in ACS patients (10.2% versus 9.0% respectively; P = 0.49) and in no-ACS patients (11.7% versus 10.7%, respectively; P = 0.67) Definite or probable device thrombosis occurred more frequently with Absorb BVS compared to Xience EES in ACS patients (4.3% versus 1.7%, respectively, P = 0.03) as well as in no-ACS patients (2.4% versus 0.2%, respectively; P = 0.002). There were no statistically significant interactions between clinical presentation and randomized device modality for TVF (P = 0.80) and for the endpoint of definite or probable device thrombosis (P = 0.17)., Conclusion: In the AIDA trial, the 2-year outcomes of PCI with Absorb BVS versus Xience EES were consistent in ACS and no-ACS patients: similar rates for TVF and consistently higher rates of definite or probable stent thrombosis under Absorb BVS versus Xience EES. There were no statistically significant interactions between clinical presentation and randomized device modality., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
42. Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion.
- Author
-
Elias J, van Dongen IM, Hoebers LP, Ouweneel DM, Claessen BEPM, Råmunddal T, Laanmets P, Eriksen E, Piek JJ, van der Schaaf RJ, Ioanes D, Nijveldt R, Tijssen JG, Henriques JPS, and Hirsch A
- Subjects
- Coronary Occlusion diagnostic imaging, Female, Heart diagnostic imaging, Heart physiology, Humans, Male, Middle Aged, Prognosis, Reproducibility of Results, ST Elevation Myocardial Infarction diagnostic imaging, Stroke Volume, Coronary Occlusion complications, Coronary Occlusion physiopathology, Magnetic Resonance Imaging methods, ST Elevation Myocardial Infarction complications, ST Elevation Myocardial Infarction physiopathology
- Abstract
Objectives: Global left ventricular (LV) function is routinely used to assess cardiac function; however, myocardial strain is able to identify more subtle dysfunction. We aimed to determine the recovery and prognostic value of featuring tracking (FT) cardiovascular magnetic resonance (CMR) strain in ST-segment elevation myocardial infarction (STEMI) patients with a concurrent chronic total occlusion (CTO)., Methods: In the randomized EXPLORE trial, there was no significant difference in global LV function after percutaneous coronary intervention (PCI) of the CTO, compared with no-CTO PCI, post-STEMI. In the current study, we included 200 of the 302 EXPLORE patients with a baseline CMR, of which 180 also had 4-month follow-up (serial) CMR. Global longitudinal strain (GLS) was calculated from 3 long-axis views. Global circumferential strain (GCS) and segmental strain were calculated from 3 short-axis views (basal, mid, and apical)., Results: Global strain significantly improved at 4 months (GLS ∆ - 1.8 ± 4.3%, p < 0.001; GCS ∆ - 1.7 ± 4.7%, p < 0.001); however, there was no treatment effect of CTO-PCI on strain recovery. GLS was a significant predictor for 4 months of LV ejection fraction (p = 0.006), incremental to other CMR parameters including infarct size. For mortality, infarct size remained the strongest predictor. On regional level, segmental strain independently predicted recovery in the dysfunctional segments (p < 0.001)., Conclusions: Global and segmental myocardial strains significantly improved over time, with no effect of CTO-PCI. Global strain was associated with outcome and segmental strain was an independent predictor for regional LV recovery in the dysfunctional CTO territory. Further research is needed to determine the additional prognostic value of strain beyond routine CMR parameters., Key Points: • In STEMI patients with a concurrent CTO, strain significantly improves over time, regardless of CTO-PCI. • Global strain is an independent predictor for functional recovery, incremental to infarct size, LVEF, and clinical parameters. • Segmental strain was able to predict the recovery of wall thickening, incremental to transmural extent of infarction.
- Published
- 2020
- Full Text
- View/download PDF
43. Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLORE-trial.
- Author
-
van Veelen A, van Dongen IM, Elias J, Råmunddal T, Eriksen E, van der Schaaf RJ, Claessen BEPM, Postema PG, and Henriques JPS
- Subjects
- Aged, Angina Pectoris diagnosis, Angina Pectoris physiopathology, Chronic Disease, Coronary Occlusion diagnosis, Coronary Occlusion physiopathology, Exercise Tolerance, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Randomized Controlled Trials as Topic, Recovery of Function, Retrospective Studies, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction physiopathology, Time Factors, Treatment Outcome, Ventricular Premature Complexes etiology, Ventricular Premature Complexes physiopathology, Angina Pectoris therapy, Coronary Occlusion therapy, Electrocardiography, Exercise Test, Heart Rate, Percutaneous Coronary Intervention adverse effects, ST Elevation Myocardial Infarction therapy, Ventricular Premature Complexes diagnosis
- Abstract
Objectives: To assess the effect of chronic total occlusion percutaneous coronary intervention (CTO PCI) on ventricular ectopy (VE) and symptomatology during exercise testing., Background: During exercise, the hypoxic myocardium in the CTO-territory can act as a substrate for VE and could lead to anginal complaints., Methods: In the EXPLORE-trial, 302 ST-segment elevation myocardial infarction (STEMI)-patients were randomized to CTO PCI or no-CTO PCI. For this sub-study, we analyzed all available exercise electrocardiograms (X-ECGs) at 4 months follow-up on symptoms and electrocardiographic parameters., Results: A total of 155 X-ECGs were available, 80 in the CTO PCI group (51.6%) and 75 in the no-CTO PCI group (48.4%). There were no differences regarding exercised time, achieved endurance, ST-deviation nor maximum heart-rate. The percentage of patients experiencing chest-pain during exercise was lower in the CTO PCI group (0% vs. 8.5%, p = .03). Also, there was a trend towards a higher maximum systolic blood pressure (SBP, 185 mmHg vs. 175, p = .09). No difference in VE was found between randomization groups, but patients with successful CTO PCI had a higher frequency of VE, compared to failed and no-CTO PCI (26% vs. 8%, p = .02). This did not result in higher frequencies of sustained ventricular arrhythmias or mortality., Conclusion: In conclusion, in STEMI-patients, CTO PCI is associated with a small reduction of chest-pain during exercise and tended to be associated with an increase of maximum SBP. The observation that successful CTO PCI was associated with more VE during exercise, compared with failed/no-CTO PCI needs further exploration., (© 2019 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
44. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.
- Author
-
Kerkmeijer LSM, Tijssen RYG, Hofma SH, van der Schaaf RJ, Arkenbout KE, Kraak RP, Weevers A, Piek JJ, de Winter RJ, Tijssen JGP, Henriques JPS, and Wykrzykowska JJ
- Subjects
- Biocompatible Materials therapeutic use, Cardiovascular Agents therapeutic use, Stents, Tissue Scaffolds, Treatment Outcome, Absorbable Implants, Cardiovascular Agents administration & dosage, Drug-Eluting Stents, Everolimus therapeutic use, Immunosuppressive Agents therapeutic use, Percutaneous Coronary Intervention
- Published
- 2019
- Full Text
- View/download PDF
45. 3-Year Clinical Outcomes of the PRISON-IV Trial: Ultrathin Struts Versus Conventional Drug-Eluting Stents in Total Coronary Occlusions.
- Author
-
Zivelonghi C, Agostoni P, Teeuwen K, van der Schaaf RJ, Henriques JPS, Vermeersch PHMJ, Bosschaert MAR, Kelder JC, Tijssen JGP, and Suttorp MJ
- Subjects
- Chronic Disease, Coronary Occlusion diagnostic imaging, Coronary Occlusion physiopathology, Coronary Restenosis etiology, Coronary Thrombosis etiology, Humans, Percutaneous Coronary Intervention adverse effects, Prosthesis Design, Risk Factors, Time Factors, Treatment Outcome, Coronary Occlusion therapy, Drug-Eluting Stents, Percutaneous Coronary Intervention instrumentation
- Published
- 2019
- Full Text
- View/download PDF
46. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial.
- Author
-
Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T, and Vink MA
- Subjects
- Aged, Angioplasty, Balloon, Coronary adverse effects, Angioplasty, Balloon, Coronary mortality, Cardiovascular Agents adverse effects, Female, Fractional Flow Reserve, Myocardial, Humans, Male, Middle Aged, Netherlands, Paclitaxel adverse effects, Prospective Studies, Prosthesis Design, ST Elevation Myocardial Infarction diagnostic imaging, ST Elevation Myocardial Infarction physiopathology, Time Factors, Treatment Outcome, Angioplasty, Balloon, Coronary instrumentation, Cardiovascular Agents administration & dosage, Coated Materials, Biocompatible, Drug-Eluting Stents, Paclitaxel administration & dosage, ST Elevation Myocardial Infarction therapy
- Abstract
Objectives: This study sought to assess the efficacy and safety of a drug-coated balloon (DCB) strategy versus drug-eluting stent (DES) in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI)., Background: In primary percutaneous coronary intervention for STEMI, stenting has proved to be beneficial with regard to repeat revascularization, but not recurrent myocardial infarction or death, compared with balloon angioplasty alone. A strategy of DCB angioplasty without stenting might abolish the potential disadvantages of stent implantation while reducing the probability of restenosis observed in plain old balloon angioplasty., Methods: In the prospective, randomized, single-center REVELATION trial, we compared DCB with DES in patients presenting with STEMI. Patients with a new, nonseverely calcified culprit lesion in a native coronary artery and a residual stenosis of <50% after pre-dilatation were randomized to treatment with a DCB or DES. The primary endpoint was fractional flow reserve at 9 months, allowing for a functional measurement of the infarct-related lesion., Results: A total of 120 patients were included. At 9 months after enrolment, the mean fractional flow reserve value was 0.92 ± 0.05 in the DCB group (n = 35) and 0.91 ± 0.06 in the DES group (n = 38) (p = 0.27). One abrupt vessel closure requiring treatment occurred after treatment with DCB. Up to 9-months follow-up, 2 patients required nonurgent target lesion revascularization (1 in each group)., Conclusions: In the setting of STEMI, the DCB strategy was noninferior to DES in terms of fractional flow reserve assessed at 9 months. Furthermore, it seemed to be a safe and feasible strategy. (Revascularization With Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stenting in Acute Myocardial Infarction [REVELATION]; NCT02219802)., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
- Author
-
Tijssen RYG, Kerkmeijer LSM, Katagiri Y, Kraak RP, Takahashi K, Kogame N, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Beijk MAM, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, and Wykrzykowska JJ
- Subjects
- Coronary Thrombosis diagnostic imaging, Coronary Thrombosis etiology, Humans, Netherlands, Percutaneous Coronary Intervention adverse effects, Predictive Value of Tests, Prosthesis Design, Risk Factors, Time Factors, Treatment Outcome, Absorbable Implants, Cardiovascular Agents administration & dosage, Coronary Angiography, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Coronary Vessels diagnostic imaging, Coronary Vessels surgery, Drug-Eluting Stents, Everolimus administration & dosage, Percutaneous Coronary Intervention instrumentation
- Abstract
Due to expansion limits of the Absorb bioresorbable scaffold a meticulous implantation with correct sizing is required. We sought to investigate the clinical outcomes based on the sizing of the device related to the maximal lumen diameter measured by quantitative coronary angiography in Absorb BVS and Xience EES treated lesions in the AIDA trial. Sizing of Absorb bioresorbable vascular scaffold (BVS) and Xience everolimus eluting stent (EES) was graded according to the definitions of device non-oversize and device oversize on pre-procedural angiography. Lesion-oriented outcomes (LOCE) (device thrombosis, TLR and TVMI) that occurred during 2 years follow-up were related to device non-oversized or oversized status. In the Absorb BVS group, LOCE occurred in 48 (7.4%) lesions in the oversized group and in 32 (8.2%) lesions in the non-oversized group (HR 0.91; 95% CI 0.58-1.42; p = 0.681), whereas TLR occurred in 34 (5.3%) lesions and in 23 lesions (5.9%), respectively (HR 0.89; 95% CI 0.52-1.51; p = 0.666). Definite scaffold thrombosis occurred in 11 (1.7%) device oversized treated lesions against 16 (4.1%) device non-oversized treated lesions (HR 0.41; 95% CI 0.19-0.89; p = 0.020). There were no differences in event rates between oversized and non-oversized groups in lesions treated with Xience EES. There was no significant difference in LOCE between oversized and non-oversized treated Absorb BVS and Xience EES treated lesions. Non-oversized Absorb BVS implantation was associated with a higher risk of scaffold thrombosis at complete 2 years follow-up. The majority of very late scaffold thrombosis occurred in properly sized devices.
- Published
- 2019
- Full Text
- View/download PDF
48. Five-year results of the complete versus culprit vessel percutaneous coronary intervention in multivessel disease using drug-eluting stents II (CORRECT II) study: a prospective, randomised controlled trial.
- Author
-
Fagel ND, van Nooijen FC, Maarse M, Slagboom T, Herrman JP, van der Schaaf RJ, Amoroso G, Patterson MS, Laarman GJ, Suttorp MJ, and Vink MA
- Abstract
Objectives/background: In patients with multivessel coronary artery disease (MVD) the decision whether to treat a single culprit vessel or to perform multivessel revascularisation may be challenging. The purpose of this study was to evaluate the long-term outcome of multivessel percutaneous coronary intervention (MV-PCI) versus culprit vessel only (CV-PCI) in patients with stable coronary artery disease or non-ST elevation acute coronary syndrome., Methods: In this dual-centre, prospective, randomised study a total 215 patients with MVD were randomly assigned to MV-PCI or CV-PCI. The primary endpoint was the occurrence of major adverse cardiac events (MACE) including death, myocardial infarction (MI), and repeat revascularisation. Secondary endpoints were the combined endpoint of death or MI, the individual components of the primary endpoint, and the occurrence of stent thrombosis. Patients were followed up to 5 years after enrolment., Results: The occurrence of the primary endpoint was similar at 28% versus 31% in the MV-PCI and CV-PCI group, respectively (hazard ratio [HR] 0.87, 95% confidence interval [CI]: 0.53-1.44, p = 0.59). The rate of repeat revascularisation was 15% versus 24% (HR 0.59, 95% CI 0.32 to 1.11, p = 0.11), whereas definite or probable stent thrombosis occurred in 2% versus 0% (p = 0.44)., Conclusions: In this randomised study comparing the strategies for MV-PCI and CV-PCI in patients with MVD, no difference was found in the occurrence of MACE after 5 years. We observed a numerically higher rate of death or MI and a lower rate of repeat revascularisation after MV-PCI, although these findings were not statistically significant.
- Published
- 2019
- Full Text
- View/download PDF
49. Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands.
- Author
-
Ten Haaf ME, Bax M, Ten Berg JM, Brouwer J, Van't Hof AW, van der Schaaf RJ, Stella PR, Tjon Joe Gin RM, Tonino PA, de Vries AG, Zijlstra F, Boersma E, and Appelman Y
- Abstract
Background: Sex differences in acute coronary syndrome (ACS) have been reported, but little is known about the situation in the Netherlands., Methods: This registry is a merge of available data on ACS patients in the electronic data capture systems of 11 centres with 24/7 interventional cardiology services. We included patients >18 years undergoing a cardiac catheterisation between 2010-2012. We evaluated sex differences in clinical and procedural characteristics and 1‑year mortality., Results: A total of 29,265 ACS patients (8,720 women and 20,545 men) were registered. Women were on average 4.5 years older (68.5 vs 63.0 years, p < 0.001) and had a higher prevalence of hypertension (62.7 vs 49.8%, p < 0.001) and insulin-dependent diabetes mellitus (9.6 vs 6.8%, p < 0.001) than men. Women less often presented with ST-elevation myocardial infarction (43.7% vs 47.6%, p < 0.001) and appeared to have less extensive coronary artery disease than men. Women less often underwent coronary angiography by radial access (52.5 vs 55.9%, p < 0.001). One-year mortality was higher in women than in men (7.3% and 5.6%, p < 0.001). More specific, the relationship between sex and mortality was age-dependent and showed higher mortality in women ≤71 years, but lower mortality in older women compared with men (p-interaction <0.001)., Conclusion: We found differences in clinical and procedural characteristics and outcome between women and men admitted for ACS, which are in line with other Western countries. The limitations of our registry, based on existing local databases, can be overcome by the use of the prospective Netherlands Heart Registry that is currently in development.
- Published
- 2019
- Full Text
- View/download PDF
50. Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion(from the EXPLORE Trial).
- Author
-
van Dongen IM, Elias J, García-García HM, Hoebers LP, Ouweneel DM, Scheunhage EM, Delewi R, Råmunddal T, Eriksen E, Claessen BE, van der Schaaf RJ, and Henriques JPS
- Subjects
- Aged, Chronic Disease, Coronary Angiography, Coronary Occlusion diagnosis, Coronary Occlusion surgery, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction surgery, Severity of Illness Index, Coronary Occlusion complications, Coronary Vessels diagnostic imaging, Magnetic Resonance Imaging, Cine methods, Percutaneous Coronary Intervention methods, ST Elevation Myocardial Infarction complications
- Abstract
`To analyze the impact of additional coronary artery disease, quantified by the SYNTAX (SYNergy between PCI with TAXus and cardiac surgery) score, on left ventricular ejection fraction (LVEF) and long-term outcomes in a cohort of ST-elevated myocardial infarction (STEMI) patients with a concomitant chronic total coronary occlusion (CTO). A total of 302 STEMI patients were randomized to percutaneous coronary intervention of a CTO (CTO PCI) (n = 148) or conservative CTO treatment (n = 154). SYNTAX scores were calculated by an independent corelab (Cardialysis BV, Rotterdam) at two time-points: (1) at baseline, and (2) after primary PCI in the conservative CTO arm and after CTO PCI in the invasive arm (named 'discharge SYNTAX score'). The population was divided in two groups (below or equal to the median SYNTAX score preprimary PCI, or above the median). At 4-month follow-up, the LVEF was significantly lower in patients in the group with a SYNTAX score above the group median (42.8% vs 48.5%, p = 0.001), and the SYNTAX score was an independent predictor for LVEF at 4 months (β-0.151 (SE 0.068), p = 0.028). In the group with a SYNTAX score above the group median the mortality rate was higher (10.1% vs 3.9%, p = 0.025), and there was a trend towards a higher MACE rate (15.4% vs 8.5%, p = 0.063). In conclusion, in this sub-analysis of the EXPLORE trial we observed a worse LVEF and a higher mortality rate for patients with a SYNTAX score above the median. We found that the SYNTAX score is an independent negative predictor for LVEF and an independent positive predictor for LVEDV at 4-month follow-up., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.